Hachem Ramsey R, Trulock Elbert P
Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Semin Thorac Cardiovasc Surg. 2004 Winter;16(4):350-5. doi: 10.1053/j.semtcvs.2004.09.011.
Over the past 15 years, lung transplantation has become an established treatment for a variety of end-stage lung diseases, but medium- and long-term success has been limited by a high incidence of bronchiolitis obliterans syndrome (BOS). Immune mediated injury has been recognized as the leading cause of BOS, and the term is synonymous with chronic rejection. But recently, nonimmune mechanisms, such as gastroesophageal reflux, have been recognized as potential culprits. The results of various treatment options have generally been disappointing, and BOS has emerged as the leading cause of late morbidity and mortality after lung transplantation.
在过去15年中，肺移植已成为治疗各种终末期肺病的既定疗法，但细支气管炎闭塞综合征（BOS）的高发病率限制了其中长期疗效。免疫介导的损伤已被公认为是BOS的主要原因，该术语与慢性排斥反应同义。但最近，诸如胃食管反流等非免疫机制已被视为潜在的病因。各种治疗方案的结果总体上令人失望，BOS已成为肺移植术后晚期发病和死亡的主要原因。
